Connect Biopharma HoldingsCNTB +0.42%7 Pretax Margin % is -11,449.70% as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Connect Biopharma Holdings ranks worse than 96.08% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Connect Biopharma Holdings Pretax Margin % Related Terms
Connect Biopharma Holdings Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTB vs ENLV, SMNR, MENS: Pretax Margin % Comparison
For the Biotechnology subindustry, Connect Biopharma Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Connect Biopharma Holdings (CNTB) has a Pretax Margin % of -11,449.70% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #907 out of 944 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Connect Biopharma Holdings' Pretax Margin % too high?
Connect Biopharma Holdings' current Pretax Margin % is -11,449.70%. Based on the distribution chart, Connect Biopharma Holdings ranks #907 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Pretax Margin % compare to ENLV and SMNR?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #907 out of 944 companies for Pretax Margin %. This places Connect Biopharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current Pretax Margin % is -11,449.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Pretax Margin % of -11,449.70%. The current Pretax Margin % is -11,449.70%. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Pretax Margin % is -11,449.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score
Get the complete analysis for CNTB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
